Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Dec 28;13(1):e1157. doi: 10.1002/ctm2.1157

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The in vivo anti‐tumour effect of YHC on human breast cancer MCF‐7 cells by using xenograft models. (A) The experimental flow chart for evaluating the anti‐tumour effect of YHC. (B) The tumour issues were excised and photographed after treatment with YHC for 14 days. (C) Tumour volumes were measured using calipres for each group every day. (D) Tumour weights were detected in each group. (E) The body weights of animals were recorded for each group during 14 days. (F–J) The organ index of nude mice was calculated for heart (F), liver (G), spleen (H), lung (I) and kidney (I), respectively. (K) Representative histomorphological changes of the organs were assessed after H&E staining. (L) YHC could decrease Ki‐67 expression in tumour tissues by immunohistochemistry assay. Statistical analysis was performed on the data as the mean ± SD (n = 5). ^* p < .05, ^** p < .01 versus control group.